Apollomics Inc. Annual Report - How They Did This Year

I’ve put together this guide to help you understand how Apollomics performed this year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Apollomics is a clinical-stage biotech company focused on discovering and developing treatments for cancer and autoimmune diseases. They operate using a "hub-and-spoke" model to manage clinical trials across the U.S., China, and Australia. Their success relies on moving drug candidates through trials to win regulatory approval or secure licensing deals.

2. The "Big Picture" Update

The company recently filed its annual report for the year ending December 31, 2025. Apollomics is currently a "pre-revenue" business, meaning they have not yet sold any products. Because they have no sales to cover their high operating costs, they rely entirely on cash reserves and outside funding to keep their research and development efforts moving forward.

3. Financial Health: The "Going Concern" Warning

The company has issued a formal warning that there is "substantial doubt" about their ability to stay in business.

• The Numbers: In 2025, the company lost $10.9 million. They spent $10.4 million more than they brought in, primarily on clinical trials and administrative costs.
• The Cash Crunch: As of December 31, 2025, they held $3.3 million in cash. Management notes that this is not enough to cover their projected expenses through April 2027.
• The Lifeline: To maintain operations, the company borrowed $2 million from its CEO in March 2026. Because of their limited capital, they must raise additional funds through debt or by selling more shares. If they issue new shares, it will dilute your ownership, meaning you will own a smaller percentage of the company.

4. Major Wins and Challenges

• The "All-In" Bet: The company’s future depends heavily on vebreltinib, a drug designed to inhibit c-Met. Their value is tied to the success of this one asset, and any clinical failure or regulatory delay for this drug would pose a significant threat to the company’s survival.
• A Recent Setback: The company wrote off $10 million related to uproleselan after a partner’s clinical trial failed. This loss forced the company to cut jobs and reduce expenses in 2024 to preserve cash.
• Internal Controls: The company has addressed the "material weakness" in its financial reporting identified in 2023. Management now considers their financial reporting processes to be reliable.

5. Future Outlook and Risks

Apollomics is a high-stakes, speculative investment. As an "emerging growth company," they provide less financial and executive compensation detail than larger, more established companies. Additionally, the CEO holds significant voting power, which may limit the influence of smaller shareholders and impact company strategy.

Bottom Line: This is a "do-or-die" situation. The company is running out of cash and depends entirely on the success of one drug and their ability to secure new funding. Their survival is not guaranteed. Before investing, consider whether you are comfortable with the high risk of a company that has no current revenue and faces a significant cash shortage.